Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy

Overview

Journal BioDrugs

Specialties Allergy & Immunology
Genetics
Pharmacology

Date 2022 Dec 26

PMID 36571696

Authors

Dafne Muller

Affiliations

Soon will be listed here.

Abstract

The clinical approval of immune checkpoint inhibitors is an important advancement in the field of cancer immunotherapy. However, the percentage of beneficiaries is still limited and it is becoming clear that combination therapies are required to further enhance the treatment efficacy. The potential of strategies targeting the immunoregulatory network by "hitting the gas pedal" as opposed to "blocking the brakes" is being recognized and intensively investigated. Hence, next to immune checkpoint inhibitors, agonists of co-stimulatory receptors of the tumor necrosis factor superfamily (TNF-SF) are emerging as promising options to expand the immunomodulatory toolbox. In this review the development of different categories of recombinant antibody and ligand-based agonists of 4-1BB, OX40, and GITR is summarized and discussed in the context of the challenges presented by the structural and mechanistical features of the TNFR-SF. An overview of current formats, trends, and clinical studies is provided.

Citing Articles

Generation and characterization of OX40-ligand fusion protein that agonizes OX40 on T-Lymphocytes.

Sato A, Nagai H, Suzuki A, Ito A, Matsuyama S, Shibui N Front Immunol. 2025; 15:1473815.

PMID: 39867912 PMC: 11757143. DOI: 10.3389/fimmu.2024.1473815.

Tumor necrosis factor superfamily signaling: life and death in cancer.

Ababneh O, Nishizaki D, Kato S, Kurzrock R Cancer Metastasis Rev. 2024; 43(4):1137-1163.

PMID: 39363128 PMC: 11554763. DOI: 10.1007/s10555-024-10206-6.

Deciphering Regulatory T-Cell Dynamics in Cancer Immunotherapy: Mechanisms, Implications, and Therapeutic Innovations.

Bhattacharya S, Paraskar G, Jha M, Gupta G, Prajapati B ACS Pharmacol Transl Sci. 2024; 7(8):2215-2236.

PMID: 39144553 PMC: 11320738. DOI: 10.1021/acsptsci.4c00156.

Costimulatory and Coinhibitory Immune Checkpoints in Atherosclerosis: Therapeutic Targets in Atherosclerosis?.

Nitz K, Herrmann J, Lerman A, Lutgens E JACC Basic Transl Sci. 2024; 9(6):827-843.

PMID: 39070270 PMC: 11282889. DOI: 10.1016/j.jacbts.2023.12.007.

Orchestrating NK and T cells via tri-specific nano-antibodies for synergistic antitumor immunity.

Ye Q, Zhu L, Liang J, Zhao D, Tian T, Fan Y Nat Commun. 2024; 15(1):6211.

PMID: 39043643 PMC: 11266419. DOI: 10.1038/s41467-024-50474-y.

References

Muik A, Garralda E, Altintas I, Gieseke F, Geva R, Ben-Ami E . Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. Cancer Discov. 2022; 12(5):1248-1265. PMC: 9662884. DOI: 10.1158/2159-8290.CD-21-1345. View

Peper-Gabriel J, Pavlidou M, Pattarini L, Morales-Kastresana A, Jaquin T, Gallou C . The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner. Clin Cancer Res. 2022; 28(15):3387-3399. PMC: 9662934. DOI: 10.1158/1078-0432.CCR-21-2762. View

Segal N, Logan T, Hodi F, McDermott D, Melero I, Hamid O . Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clin Cancer Res. 2016; 23(8):1929-1936. DOI: 10.1158/1078-0432.CCR-16-1272. View

Balmanoukian A, Infante J, Aljumaily R, Naing A, Chintakuntlawar A, Rizvi N . Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors. Clin Cancer Res. 2020; 26(23):6196-6203. DOI: 10.1158/1078-0432.CCR-20-0452. View

Hornig N, Kermer V, Frey K, Diebolder P, Kontermann R, Muller D . Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy. J Immunother. 2012; 35(5):418-29. DOI: 10.1097/CJI.0b013e3182594387. View

Bodmer J, Schneider P, Tschopp J . The molecular architecture of the TNF superfamily. Trends Biochem Sci. 2002; 27(1):19-26. DOI: 10.1016/s0968-0004(01)01995-8. View

Hinner M, Aiba R, Jaquin T, Berger S, Durr M, Schlosser C . Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343. Clin Cancer Res. 2019; 25(19):5878-5889. DOI: 10.1158/1078-0432.CCR-18-3654. View

Ascierto P, Simeone E, Sznol M, Fu Y, Melero I . Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol. 2010; 37(5):508-16. DOI: 10.1053/j.seminoncol.2010.09.008. View

Fu Y, Lin Q, Zhang Z, Zhang L . Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity. Acta Pharm Sin B. 2020; 10(3):414-433. PMC: 7049610. DOI: 10.1016/j.apsb.2019.08.010. View

10.

Habib-Agahi M, Phan T, Searle P . Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells. Int Immunol. 2007; 19(12):1383-94. DOI: 10.1093/intimm/dxm106. View

11.

Houot R, Goldstein M, Kohrt H, Myklebust J, Alizadeh A, Lin J . Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood. 2009; 114(16):3431-8. PMC: 2765679. DOI: 10.1182/blood-2009-05-223958. View

12.

Williams J, Horton B, Zheng Y, Duan Y, Powell J, Gajewski T . The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. J Exp Med. 2017; 214(2):381-400. PMC: 5294847. DOI: 10.1084/jem.20160485. View

13.

Oberst M, Auge C, Morris C, Kentner S, Mulgrew K, McGlinchey K . Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein. Mol Cancer Ther. 2018; 17(5):1024-1038. PMC: 5932227. DOI: 10.1158/1535-7163.MCT-17-0200. View

14.

Compte M, Harwood S, Martinez-Torrecuadrada J, Perez-Chacon G, Gonzalez-Garcia P, Tapia-Galisteo A . Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR. Front Immunol. 2021; 11:614363. PMC: 7817978. DOI: 10.3389/fimmu.2020.614363. View

15.

Croft M . The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009; 9(4):271-85. PMC: 2737409. DOI: 10.1038/nri2526. View

16.

Yi M, Niu M, Xu L, Luo S, Wu K . Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol. 2021; 14(1):10. PMC: 7792099. DOI: 10.1186/s13045-020-01027-5. View

17.

Liu L, Wu Y, Ye K, Cai M, Zhuang G, Wang J . Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking. Front Pharmacol. 2022; 13:924197. PMC: 9295861. DOI: 10.3389/fphar.2022.924197. View

18.

Palazon A, Teijeira A, Martinez-Forero I, Hervas-Stubbs S, Roncal C, Penuelas I . Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res. 2011; 71(3):801-11. DOI: 10.1158/0008-5472.CAN-10-1733. View

19.

. 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018. J Immunother Cancer. 2018; 6(Suppl 1):114. PMC: 6220480. DOI: 10.1186/s40425-018-0422-y. View

20.

Qi X, Li F, Wu Y, Cheng C, Han P, Wang J . Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity. Nat Commun. 2019; 10(1):2141. PMC: 6526162. DOI: 10.1038/s41467-019-10088-1. View